Pharmacokinetics of the iron chelator desperrioxamine as affected by liposome encapsulation: potential in treatment of chronic hemosiderosis.
D000818:Animals; D002214:Capsules; D002908:Chronic Disease; D003676:Deferoxamine / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D005260:Female; D006486:Hemosiderosis / Q000188:drug therapy*; D007275:Injections, Intravenous; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D007700:Kinetics; D008081:Liposomes; D051379:Mice; D014018:Tissue Distribution
D002214:Capsules; D007502:Iron Chelating Agents; D008081:Liposomes; D003676:Deferoxamine